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Abstract
The immune system may mediate anti-tumor responses in chronic lymphocytic leukemia (CLL) which may affect disease
progression and survival. In this study, we analyzed the immune characteristics of 99 consecutive previously diagnosed CLL
patients and 50 healthy controls. The distribution of lymphocyte subsets at diagnosis was retrospectively analyzed.
Compared with controls, leukemia patients showed an expansion of NK and CD8 T cells at diagnosis. The relative number of
CD8 T cells at diagnosis was associated with time to treatment, suggesting that CD8 T cells may modify disease progression.
The distribution of lymphocyte subsets was analyzed again when patients were enrolled in this study. The median time
since these patients were diagnosed was 277 weeks. Compared with diagnosis, the absolute number of CD8 T cells
significantly decreased in these patients, reaching similar values to healthy controls; however NK cells kept significantly
elevated overtime. Nevertheless, NK cells showed an impaired expression of NKG2D receptor and a defective cytotoxic
activity. This down-regulation of NKG2D expression was further enhanced in patients with advanced and progressive
disease. Additionally, membrane NKG2D levels significantly decreased on CD8 T cells, but a significant increase of NKG2D+
CD4+ T cells was observed in CLL patients. The cytotoxic activity of NK cells was diminished in CLL patients; however the
treatments with IL-2, IL-15, IL-21 and lenalidomide were able to restore their activity. The effect of IL-2 and IL-15 was
associated with the increase of NKG2D expression on immune cells, but the effect of IL-21 and lenalidomide was not due to
NKG2D up-regulation. The expansion of NK cells and the reversibility of NK cell defects provide new opportunities for the
immunotherapeutic intervention in CLL.
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Introduction
Chronic lymphocytic leukemia (CLL) is the most common adult
leukemia in Western countries. It is characterized by a clonal
accumulation of mature malignant B cells in blood, bone marrow
and lymphoid organs. There is a marked clinical heterogeneity in
this disease that is associated with a heterogeneous array of genetic
and molecular defects [1]. The complexity of this malignancy is
further increased by the interaction of leukaemia cells with the
microenvironment [2]. Leukaemia cells closely interact with
accessory and immune cells that regulate their trafficking, survival
and proliferation [3]. Additionally, the immune system may
mediate anti-tumor responses in CLL which may affect disease
progression and survival [4–6]. Nevertheless, patients progressively
develop multiple immune defects, including hypogammaglobulin-
emia, impairment of the function of T, NK and dendritic cells, as
well as alterations in the cytokine network [7]. Likewise, patients
with advanced disease frequently develop a severe immunodefi-
ciency.
NKG2D is an activating receptor expressed by NK and T cells
that plays a key role in the immune response against cancer [8,9].
NKG2D is the receptor for MHC class I-related chain A and B
(MICA/B) and UL16-binding proteins 1–6 (ULBP1-6), which are
restrictedly expressed in benign cells, but are up-regulated in
stressed and transformed cells, triggering a potent anti-tumour
immune response [10–12]. Leukaemia cells of CLL patients
express low membrane levels of NKG2D ligands and shed soluble
NKG2D ligands, which confers poor prognosis to CLL patients
[13,14]. Accordingly, a reduction of NKG2D expression on CD8
T cells in a cohort of CLL patients with high levels of serum
soluble MICA (sMICA) has been reported [15].
In this study, we analyzed the evolution of the number and the
characteristics of the immune cells with the progression of CLL.
We also examined the expression of NKG2D receptor on these
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cells, which may play a key role in the anti-tumor activity against
leukemia cells.
Material and Methods
Patient and CLL samples
99 consecutive previously diagnosed CLL patients and 50
healthy matched controls were analyzed in this study (Table 1).
Patients were diagnosed between 1982 and 2011. The median
time since they were diagnosed was 277 weeks. As previously
described, patients were classified as having stable (n = 38) or
progressive disease (n = 61) [16]. 27 patients had received
chemotherapeutic treatment; however none of them received
any treatment 6 months before being enrolled in this study.
Immunological characteristics of these patients at diagnosis were
retrospectively analyzed. Clinical and immunological characteris-
tics of the patients were analyzed when patients were enrolled in
this study. For that purpose, peripheral blood mononuclear cells
(PBMCs) from freshly isolated blood obtained from patients and
controls were purified by Ficoll-Paque (Pharmacia) density
centrifugation. NK cells were isolated using the EasySep NK Cell
Enrichment kit (StemCell Technologies). This study was approved
by the Hospital Universitario Central de Asturias Ethics Com-
mittee and written informed consent was obtained from all
patients and controls.
Flow cytometry
Diagnosis of CLL for each patients was confirmed by flow
cytometry, which revealed a typical CD19+, CD20+, CD5+,
CD23+ and Ig light chain (k or l) restricted phenotype. Absolute
counts of the main PBMCs subsets, including CD4 and CD8 T
cells, B cells and NK cells were carried out by flow cytometry upon
diagnosis. The distribution of these subsets of lymphocytic cells
and the membrane expression of NKG2D were also analyzed at
the time of patient enrollment. The protocol for B-cell chronic
lymphoproliferative diseases used in all cases included the
following antibody conjugates: anti-CD3-FITC, anti-CD4-PerCP,
Table 1. Clinical characteristics of CLL patients.
Characteristic n=99
Age at diagnosis (years) 68,2
Gender: Male/Female 63/36
Rai stage at diagnosis (%)
Low: 0/I 45
Intermediate: II/III 33
High IV/V 21
Binet
A 67
B 15
C 17
Progressive/stable disease 61/38
Lymphocytes (x109/L) 13.2 (0,6–300.1)*
Affected Lymph nodes
0 58
1 15
2 14
$3 12
ECOG
0–1 69
2 22
3 8
4 2
CD38 (%)** 20%
Gammaglobulins (gr/L) 9.0 (4–20.1)*
IgG (gr/L) 9.39 (3.6–21.7)*
IgA (gr/L) 1.6 (0.1–4.4)*
IgM (gr/L) 0.5 (0.1–4)*
LDH (U/L) 287 (142–928)*
b2-microglobulin (mg/L) 3.14 (0.9–18)*
MBC duplication in less than 1 year (%) 32%
MBC: monoclonal B-cells clone.
* median and range.
** Positive (.30%).
doi:10.1371/journal.pone.0108326.t001
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anti-CD8-CF-Blue, anti-CD56-APC, anti-CD19-APC (all from
Immunostep), anti-CD3-PECy7 (eBioscience) and anti-NKG2D-
PE (Miltenyi Biotec). The populations of cells were defined as
follows: CD4 T cells were defined as CD3+CD4+, CD8 T cells
were defined as CD3+CD8+, B cells were defined as CD19+ and
NK cells were defined as CD3-CD56+. Cells were analyzed on a
BD Biosciences FACSCanto II cytometer and data were analyzed
by FACSDiva software (Beckton Dickinson).
Cell lines and cell cultures
K562 cells were obtained from ATCC and were grown in
RPMI-1640, 2 mM L-glutamine and gentamicin (complete media)
supplemented with 10% heat-inactivated human AB serum.
26106 PBMCs were cultured in complete media containing
10% of human AB serum in the presence of IL-2 (5 ng/ml), IL-15
(25 ng/ml), IL-21 (20 ng/ml) (all from Peprotech) for 48 h or
lenalidomide (1 mM) (Celgene) for 7 days. Cultured cells were
incubated with a mixture of fluorescent-labelled antibodies: anti-
CD3-FITC, anti-CD4-PerCP, anti-CD8-CF-Blue, anti-CD56-
APC or anti-NKG2D-PE for 15 min. After washing, cells were
analyzed by flow cytometry.
CD107a degranulation assay and cytotoxic assay
CD107a lysosome-associated membrane protein-1 (LAMP-1)
was used to measure NK, NKT-like and CD8 cell cytotoxic
activity. PBMCs from healthy donors stimulated with IL-2 (5 ng/
ml), IL-15 (25 ng/ml), IL-21 (20 ng/ml) for 48 hours or
lenalidomide (1 mM) for 7 days were incubated with target K562
cells at an Effector: Target (E:T) ratio of 5:1 in complete media
supplemented with human AB serum and BD GolgiStop (BD
Biosciences). As a positive control of degranulation, PBMCs were
stimulated with PMA (50 ng/ml) and ionomycin (250 ng/ml)
(both from Sigma-Aldrich). The anti CD107a-PE antibody (BD
Biosciences) was added to the plate during the incubation. After
the incubation, samples were stained for CD3, CD4, CD8 and
CD56 expression and were analyzed by flow cytometry.
Statistical analysis
Gaussian distribution of values was tested by Kolmogorov-
Smirnov test. Relationship between continuous variables and
categorical prognostic variables was evaluated by Mann–Whitney
and Kruskal–Wallis tests. The Wilcoxon Matched-Pairs Signed
Ranks test was utilized for intra-group comparisons. Spearman’s
rank correlation test was used to analyze the correlation between
the biological parameters. Time to treatment was defined as the
time from diagnosis to time of first therapy. Time to treatment was
analyzed using the approach of Kaplan and Meier. P-values ,
0.05 were considered significant. All analyses were conducted with
SPSS, version 15.0.
Results
CD8 T cells and NK cells populations were expanded at
diagnosis of CLL
99 consecutive previously diagnosed CLL patients and 50
healthy matched controls were analyzed in this study (Table 1).
The distribution of lymphocyte subsets in these patients at
diagnosis was retrospectively analyzed. At diagnosis, additionally
to an increase of B cells, CLL patients showed a marked increase
of NK cells (median of 0.436 vs. 0.2096109 cells/L; p,0.0001)
and T cells (2.048 vs. 1.676109 cells/L; p,0.0001) compared with
controls (Fig. 1). There was an increase of CD8 T cells (0.723 vs.
0.2716109/L; p,0.0001), but no differences were observed in
CD4 T cells. Of note, significant correlations between the absolute
numbers of B cells at diagnosis and the numbers of T cells
(r = 0.31, p = 0.02), CD4 T cells (r = 0.274, p = 0.01), CD8 T cells
(r = 0.362, p = 0.01) and NK cells (r = 0.246, p = 0.02) were
observed.
CD8 T cells, but not NK cells, decreased with the
progression of CLL
The distribution of lymphocyte subsets in patients was again
analyzed by flow cytometry when patients were enrolled in this
study. The median time since the patients were diagnosed was 277
weeks. At that stage of the disease, patients showed a significant
increase of B cells compared with the absolute numbers at
diagnosis (Fig. 2A). A concomitant decrease in the absolute
number of CD8 T cells (0.419 vs. 0.7236109/L, p,0.0001),
reaching values similar to healthy controls (0.419 vs. 0.2716109/
L), was observed (Fig. 2B). No differences in CD4 T cells were
Figure 1. Absolute numbers of immune cells at diagnosis of CLL. Absolute numbers of B cells (CD19+), CD4 T cells (CD3+CD4+), CD8 T cells
(CD3+CD8+) and NK cells (CD3-CD56+) at diagnosis of 99 CLL patients were compared with 50 healthy controls. Horizontal bars, boxes and whiskers
represent median, 25%/75% quartiles and range, respectively. (***p,0.001).
doi:10.1371/journal.pone.0108326.g001
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detected. Similar to diagnosis, the number of NK cells kept
significantly higher than controls (0.398 vs. 0.2096109/L; p,
0.0001) (Fig. 2B and 2C).
The changes in the lymphocyte subsets overtime were also
analyzed in relation with the clinical characteristics of the patients.
The decrease of CD8 T cells was not significantly different
between patients with progressive and stable disease (not shown).
There were also no differences in relation with the chemotherapy
treatment. Patients who were previously treated (n= 27) showed a
non-significant decrease of NK cells (0.636 vs. 0.3776109/L) and,
a slight increase in CD8 T cells (0.566 vs. 0.6436109/L) compared
with non-treated ones, (Fig. 2D and E).
26 CLL patients developed a second malignancy, mainly skin
(n = 8), prostate (n = 4), colon (n= 3) and bladder (n = 3) cancers.
Compared with the absolute numbers at diagnosis, those patients
who developed a second malignancy had a higher loss in the
absolute numbers of NK cells (20.139 vs. 20.1226109/L,
p = 0.04), CD8 T cells (20.668 vs. 20.2936109/L; p= 0.1) and
CD4 T cells (20.197 vs. 20.0776109/L; p = 0.4) than those who
did not suffer a second malignancy, in that deterioration of the
immune system may be associated with the development of these
tumors.
Prognosis significance of CD8 count in CLL patients
The relative numbers of T and NK cells at diagnosis have been
associated with clinical outcome in CLL [4,5]. Thus, we analyzed
whether the relative numbers of T and NK cells at diagnosis
influence the time to treatment. The relative numbers of T cells
and NK cells were analyzed by calculating the ratio between the
numbers of T/NK cells and Monoclonal B Clone (MBC) (T/NK
cells: MBC ratio) as previously described [4]. Patients with relative
CD8 T cell count .0.03 showed a significantly higher time to
treatment than those with lower numbers of CD8 T cells (Fig. 3),
suggesting that CD8 T cells may modify disease progression. No
other association was observed.
Figure 2. Effect of the disease progression on the absolute numbers of B cells, CD4 T cells, CD8 T cells and NK cells. (A and B) Absolute
numbers of B cells, CD8 T cells, NK cells and CD4 T cells were re-evaluated after the evolution of the disease, and they were compared with the values
at diagnosis. The median time since the patients were diagnosed was 277 weeks. (C) Absolute NK cell number at the follow-up evaluation was
compared with healthy controls. (D and E) Comparison of the absolute numbers of CD8 T cells and NK cells at the follow-up evaluation, according to
the chemotherapy treatment. (**p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0108326.g002
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NKG2D membrane expression is decreased on NK cells
and increased on CD4 T cells of CLL patients
Flow cytometry analysis showed that NKG2D was expressed on
T and NK cells, but it was absent in B cells (CD19+) of patients
and controls (Fig. 4A). Compared with controls, NKG2D
expression was markedly reduced on NK cells of patients (mean
fluorescence intensity (MFI) of 2878 vs. 4778, p,0.0001), and on
CD8 T cells (5202 vs. 5882, p = 0.003) (Fig. 4B). The percentage
of CD4+NKG2D+ T cells was significantly higher in patients than
in controls (median of 8% vs. 2.7%, p= 0.001) (Fig. 4C). CD4+
NKG2D+ T cells of CLL patients comprised a heterogeneous
population of cells, as 51% of them were CD4+CD8+, 18% were
CD4+CD56+ and 30% lacked CD8 and CD56 expression.
The expression of NKG2D on NK cells was reduced in
patients with progressive and advanced disease
The association between NKG2D expression and the clinical
characteristics of CLL patients was next analyzed. NKG2D
expression on NK cells was significantly decreased in patients with
progressive disease (p = 0.017), in patients with advanced Binet
stage (p = 0.001) and in high risk patients (Rai stage III and IV)
(p = 0.04) (Fig. 5A, B and C). Further, the expression of NKG2D
receptor on NK cells negatively correlated with the number of
affected lymph nodes (r =20.254, p = 0.01) and ECOG (r =2
0.353, p,0.001); but it directly correlated with the sera levels of
lactate dehydrogenase (r = 0.277, p = 0.007). The percentage of
CD4+NKG2D+ T cells was decreased in patients with advanced
Binet stage disease (p = 0.03) (Fig. 5D).
The expression of NKG2D and the cytotoxic activity of NK
cells may be restored in CLL patients
We next studied whether NKG2D expression can be induced
upon exposure to immunomodulatory molecules. Treatment of
PBMCs obtained from CLL patients with IL-2 and IL-15 for
48 hours significantly up-regulated the expression of NKG2D on
NK cells and CD8 T cells (Fig. 6A). No effect on NKG2D
expression was observed with IL-21 or lenalidomide, even after 14
days of treatment (not shown).
Further, CD107a degranulation assay showed that NK cells of
CLL patients had a diminished cytotoxic activity compared with
healthy controls (Fig. 6B). Nevertheless, their cytotoxic activity was
significantly enhanced when immune cells were previously
stimulated with IL-2, IL-15, and IL-21 for 48 hours or
lenalidomide for 7 days (Fig. 6C).
Discussion
Here, we analyzed the immune characteristics of a cohort of
previously diagnosed CLL patients. The most relevant results of
our study are: (i) CD8 T cells were increased at diagnosis of CLL,
and the relative number of CD8 T cells at diagnosis was associated
with the clinical outcome of the patients. (ii) This initial expansion
of CD8 T cells decreased overtime with the evolution of the
disease, and it was not associated with the chemotherapy
treatment. (iii) The number of NK cells was significantly expanded
overtime in CLL. (iv) The expression of NKG2D was decreased on
NK and CD8 T cells, but it was increased on CD4 T cells of
previously diagnosed CLL patients. (v) The reduction of NKG2D
expression on NK cells was further enhanced in patients with
advanced and progressive disease. (vi) The expression of NKG2D
and the cytotoxic activity of NK cells of CLL patients were
restored with immunomodulatory molecules and cytokines.
The expansion of anti-tumor immune cells, mainly CD8 T cells
and NK cells, has been described in several haematological
malignancies [17–23]. Nevertheless, the expansion of T cells has
not been observed in a pre-leukemic monoclonal B lymphocytosis
[24], suggesting that the expansion of immune cells in CLL may
be associated with the transformation of B cells. This is in
agreement with the fact that we observed a significant correlation
between the number of leukemic cells at diagnosis and the number
of T and NK cells [24]. This expansion of CD8 T cells is
associated with the clinical outcome suggesting that CD8 T cells
may modify the progression of the disease. However, the potential
anti-leukemic role of these expanded T cells remains to be
elucidated.
Additionally, we further observed that the initial expansion of
CD8 T cells decreased overtime after the diagnosis of the disease,
reaching values similar to those observed in healthy controls. In
the course of progression of CLL, patients develop multiple
immune defects, which are associated with a severe immunode-
ficiency [7]. In agreement, the deterioration of the immune system
observed in our study was associated with a significant increase of
second malignancies in CLL patients. This may probably reflect
the consequence of the immune evasion mechanisms developed by
leukemia cells [25].
NK cells were also expanded in CLL patients at the diagnosis of
the disease, but, unlike T cells, their number was kept elevated
when they were re-evaluated after the diagnosis. In spite of the fact
that the expansion of NK cells in CLL patients has been associated
with better prognosis [5], we could not find any correlation
between NK cell numbers and the prognosis of the patients. In
agreement, NK cell activity in CLL patients is highly impaired and
leukaemia cells are highly resistant to NK cell cytotoxicity [26,27].
In this scenario, we observed a down-regulation of NKG2D
expression that may contribute to the deficiency of NK cell
function. This decrease of NKG2D expression was further
augmented in patients with advanced disease, suggesting that
leukaemia cells may be involved in the repression of NKG2D
expression. In agreement, we previously reported that the
Figure 3. Prognostic significance of CD8 T cells in CLL. Kaplan-
Meier curves were used to analyze the prognostic significance of the
relative numbers of CD8. The relative number of CD8 T cells were
analyzed by calculating the ratio between the numbers of CD8 T cells
and Monoclonal B Clone (MBC) (T/NK cells: MBC ratio) as previously
described (4). Patients with relative CD8 T cell count .0.03 (green line)
showed significantly higher time to treatment than those with lower
numbers of CD8 T cells (blue line). Statistical differences were analyzed
by long-rank test.
doi:10.1371/journal.pone.0108326.g003
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reduction of NKG2D expression in CLL may be due to the
chronic exposure to released soluble NKG2D ligands [15].
Additionally, we observed a profound deregulation of the
expression of NKG2D on other immune cells. In this sense,
NKG2D levels slightly, but significantly, decreased in CD8 T cells.
Further, an increase of NKG2D expression on CD4 T cells was
also detected. Low levels of NKG2D+CD4+ T cells are present in
healthy individuals, but this population may be expanded in some
chronic and autoimmune diseases [28–30]. NKG2D+CD4+ T
cells with both immunosuppressive and anti-tumor activity have
been described. Our results suggest that NKG2D+CD4+ T cells
are a heterogeneous population of cells in CLL, but the increase of
these cells in early stage Binet patients argues against an
immunosuppressive role for this population.
Figure 4. Expression of NKG2D on immune cells of CLL patients. (A) PBMCs obtained from CLL patients were stained with CD3-, CD4-, CD8-,
CD56- and NKG2D-conjugated antibodies. Flow cytometry analysis of one representative patient is shown. (B) The figure shows the comparison of
the MFI of NKG2D surface expression in NK cells, CD8 T cells and NKT-like cells between patients and controls. (C) Comparison of the percentage of
NKG2D+CD4 T cells between patients and controls. (**p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0108326.g004
NK Cells and NKG2D Expression in CLL
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Remarkably, our findings indicate that the impairment of
NKG2D expression on immune cells of CLL patients is reversible.
Thus, the expression of NKG2D in cytotoxic cells of CLL patients
can be restored upon treatment with cytokines and immunomod-
ulatory drugs [31–34]. IL-2 and IL-15 induced NKG2D
expression on immune cells, and stimulated NK cell cytotoxicity.
IL-21 and lenalidomide also stimulated the cytotoxic activity of
NK cells; however, independently of the induction of NKG2D
expression.
Overall, our experiments indicate that a profound deregulation
of the immune system occurs with the progression of CLL.
Noteworthy, the expansion of NK cells, and the reversibility of
their defects, provides new opportunities for immunotherapeutic
intervention in this disease.
Figure 5. Association between clinical parameters of CLL patients and the expression of NKG2D. NKG2D expression on NK cells was
analyzed in patients stratified by the existence of stable and progressive disease (A), Binet stage (B) and Rai stage (C). The percentage of NKG2D+
CD4+ T cells in CLL patients was analyzed according to the Binet stage. (**p,0.01).
doi:10.1371/journal.pone.0108326.g005
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Figure 6. Effect of immunomodulatory molecules in the expression of NKG2D and the cytotoxic activity of NK cells of CLL patients.
(A) PBMCs purified from CLL patients were incubated with IL-2 (5 ng/ml), IL-15 (25 ng/ml), IL-21 (20 ng/ml) for 48 hours or lenalidomide (1 mM) for 7
days and the expression of NKG2D on NK cells, CD8 T cells and NKT-like cells was analyzed by flow cytometry. Bars represent the mean and the
standard deviation of the fold induction of NKG2D expression. (*p,0.05). (B) PBMCs from healthy donors and CLL patients were incubated with K562
cells at an E:T ratio of 5:1 for 4 hours. The expression of CD107a in NK cells was evaluated by flow cytometry. The bars represent the mean and the
standard deviation of the percentage of CD107a+ NK cells obtained in controls and patients. (C) PBMCs from CLL patients were incubated with IL-2
(5 ng/ml), IL-15 (25 ng/ml), IL-21 (20 ng/ml) for 48 hours or lenalidomide (1 mM) for 7 days, and then they were incubated with K562 cells at an E:T
ratio of 5:1 for 4 hours. The expression of CD107a in NK cells was evaluated by flow cytometry. (*p,0.05**; p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0108326.g006
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